Cheung K L, Willsher P C, Pinder S E, Ellis I O, Elston C W, Nicholson R I, Blamey R W, Robertson J F
City Hospital, Nottingham, UK.
Breast Cancer Res Treat. 1997 Sep;45(3):219-24. doi: 10.1023/a:1005828731462.
This study reports on factors predicting response to second-line endocrine therapy in 250 patients with breast cancer for which they were assessable for response by the International Union Against Cancer (UICC) criteria. Clinical details relating to first-line endocrine therapy were available for all patients. We have not included in this study patients who received first-line endocrine therapy but did not or have not yet proceeded to second-line hormone therapy--e.g. died from rapidly progressive disease, started chemotherapy for rapidly progressive disease, or remained in long-term remission on first-line endocrine therapy. One hundred and fifty nine patients (72%) achieved remission (objective response and static disease [OR + SD]) on first-line endocrine therapy with a median duration of 19 months. For second-line endocrine therapy the remission rate was 53% (132/225) with a median duration of 15 months. Tumour grade and oestrogen receptor status of the primary tumour were shown to be independent predictors of response to second-line endocrine therapy while response to first-line endocrine therapy was a predictor of the duration of response to second-line endocrine therapy. In the sub-group of patients who showed OR or SD to both first and second-line therapies, there was no correlation between the time to progression (TTP) on first and second-line therapies.
本研究报告了250例乳腺癌患者二线内分泌治疗反应的预测因素，这些患者可根据国际抗癌联盟（UICC）标准评估反应。所有患者均有一线内分泌治疗的临床详细资料。本研究未纳入接受一线内分泌治疗但未或尚未进行二线激素治疗的患者，例如死于快速进展性疾病、因快速进展性疾病开始化疗或在一线内分泌治疗中长期缓解的患者。159例患者（72%）在一线内分泌治疗中获得缓解（客观反应和疾病稳定[OR + SD]），中位缓解持续时间为19个月。二线内分泌治疗的缓解率为53%（132/225），中位缓解持续时间为15个月。原发肿瘤的肿瘤分级和雌激素受体状态被证明是二线内分泌治疗反应的独立预测因素，而一线内分泌治疗的反应是二线内分泌治疗反应持续时间的预测因素。在一线和二线治疗均显示OR或SD的患者亚组中，一线和二线治疗的疾病进展时间（TTP）之间无相关性。
